Allarity Therapeutics (ALLR) Non-Current Assets (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Non-Current Assets came in at $420000.0 in Q1 2026, up 36.36% YoY from $308000.0 in Q1 2025, and up 27.27% on a QoQ basis from $330000.0 in Q4 2025.
Allarity Therapeutics (ALLR) Non-Current Assets (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Non-Current Assets data on file, last reported at $420000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 36.36% year-over-year to $420000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 86.26% YoY) and the FY2025 annual result came in at $330000.0, up 6.8% from the prior year.
- Non-Current Assets rose to $420000.0 in Q1 2026, from $330000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $14.1 million in Q1 2022 to a low of $12000.0 in Q3 2024.
- A 5-year average of $6.4 million and a median of $9.6 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 99.87% — and 2025, when it surged 2650.0%.
- Tracing ALLR's Non-Current Assets over 5 years: stood at $9.6 million in 2022, then gained by 3.29% to $9.9 million in 2023, then plunged by 96.88% to $309000.0 in 2024, then grew by 6.8% to $330000.0 in 2025, then climbed by 27.27% to $420000.0 in 2026.
- The last three Non-Current Assets figures came in at $420000.0 (Q1 2026), $330000.0 (Q4 2025), and $330000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - | 386,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 420,000.00 |
| Dec 31, 2025 | 330,000.00 |
| Sep 30, 2025 | 330,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 309,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 9.57 Mn |
| Mar 31, 2024 | 9.67 Mn |
| Dec 31, 2023 | 9.89 Mn |
| Sep 30, 2023 | 9.49 Mn |
| Jun 30, 2023 | 9.74 Mn |
| Mar 31, 2023 | 9.74 Mn |
| Dec 31, 2022 | 9.58 Mn |
| Sep 30, 2022 | 12.07 Mn |
| Jun 30, 2022 | 13.11 Mn |
| Mar 31, 2022 | 14.08 Mn |
| Dec 31, 2021 | 28.23 Mn |
| Sep 30, 2021 | 29.35 Mn |
| Dec 31, 2020 | 31.69 Mn |